CSF@E-Hn: A bone marrow-targeted nanosystem for advanced treatment of hematological malignancies

Yinyan Jiang; Jianqiao Shentu; Yalu Chen

doi:10.1002/mog2.70006

MEDCOMM - Oncology ›› 2024, Vol. 3 ›› Issue (4) : e70006 DOI: 10.1002/mog2.70006

HIGHLIGHT

CSF@E-Hn: A bone marrow-targeted nanosystem for advanced treatment of hematological malignancies

Author information +

History +

PDF

Cite this article

Download citation ▾

Yinyan Jiang, Jianqiao Shentu, Yalu Chen. CSF@E-Hn: A bone marrow-targeted nanosystem for advanced treatment of hematological malignancies. MEDCOMM - Oncology, 2024, 3(4): e70006 DOI:10.1002/mog2.70006

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	ZhangY, DengY, ZhaiY, et al. A bispecific nanosystem activates endogenous natural killer cells in the bone marrow for haematologic malignancies therapy. Nat Nanotechnol. 2024;19(10):1558-1568.

[2]	ParkerJ, Hockney S, BlaschukOW, PalD. Targeting n-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia. Expert Rev Mol Med. 2023;25:e16.

[3]	XuB, HuR, LiangZ, et al. Metabolic regulation of the bone marrow microenvironment in leukemia. Blood Rev. 2021;48:100786.

[4]	FuhrmannG, Herrmann IK, StevensMM. Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today. 2015;10(3):397-409.

[5]	TianT, ZhangHX, HeCP, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018;150:137-149.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).